JPH0644878B2 - Bile acid measurement reagent - Google Patents
Bile acid measurement reagentInfo
- Publication number
- JPH0644878B2 JPH0644878B2 JP60290098A JP29009885A JPH0644878B2 JP H0644878 B2 JPH0644878 B2 JP H0644878B2 JP 60290098 A JP60290098 A JP 60290098A JP 29009885 A JP29009885 A JP 29009885A JP H0644878 B2 JPH0644878 B2 JP H0644878B2
- Authority
- JP
- Japan
- Prior art keywords
- hsdh
- enzyme
- bile acid
- acid
- optimum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003613 bile acid Substances 0.000 title claims description 28
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 13
- 238000005259 measurement Methods 0.000 title description 9
- 101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 claims description 35
- 241000187654 Nocardia Species 0.000 claims description 6
- 241000187681 Nocardia sp. Species 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 2
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 description 35
- 102000004190 Enzymes Human genes 0.000 description 35
- 238000000034 method Methods 0.000 description 25
- 239000002609 medium Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000006071 cream Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000003774 sulfhydryl reagent Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 description 3
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000928746 Homo sapiens Dehydrogenase/reductase SDR family member 9 Proteins 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GMKMEZVLHJARHF-WHFBIAKZSA-N LL-2,6-diaminopimelic acid Chemical compound OC(=O)[C@@H](N)CCC[C@H](N)C(O)=O GMKMEZVLHJARHF-WHFBIAKZSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000589776 Pseudomonas putida Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- -1 aminohexyl Chemical group 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010051914 Cholesterosis Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000589518 Comamonas testosteroni Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710159606 FMN reductase (NADH) RutF 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は胆汁酸測定用試薬に関する。更に詳細には、至
適pHが8.0 〜9.0 にあり且つ、3α−ヒドロキシステロ
イドに対し基質特異性を有する3α−ヒドロキシステロ
イドデヒドロゲナーゼ(以下、3α−HSDHと略す)
を含有する系からなる胆汁酸測定用試薬に関する。TECHNICAL FIELD The present invention relates to a reagent for measuring bile acid. More specifically, 3α-hydroxysteroid dehydrogenase (hereinafter, abbreviated as 3α-HSDH) having an optimum pH of 8.0 to 9.0 and having substrate specificity for 3α-hydroxysteroid.
And a reagent for measuring bile acid, which comprises a system containing
本胆汁酸測定用試薬は、臨床検査分野で肝胆道系疾患の
検査法として血中の胆汁酸濃度を測定する際に用いられ
うる。The reagent for measuring bile acid can be used for measuring the concentration of bile acid in blood as a test method for hepatobiliary diseases in the field of clinical testing.
従来の技術 従来より胆汁酸の測定には、イムノアッセイ法,ガスク
ロマトグラフイー法,薄層クロマトグラフイー法,高速
液体クロマトグラフイー法等があるが、方法によっては
特定の胆汁酸しか測定できなかったり、前処理が煩雑で
分離が不充分なこと、さらには血中濃度を測定するには
感度が低い等の問題点がある。これらを解決する為、総
胆汁酸の測定には3α−HSDHを用いる簡便で特異性
が高く、感度の良い方法が採用されている。その酵素法
による胆汁酸定量は、日常のルーチン検査法,マススク
リーニング法として優れている。Conventional technology Conventionally, there have been immunoassay methods, gas chromatographic methods, thin-layer chromatographic methods, high-performance liquid chromatographic methods, etc. for measuring bile acids, but depending on the method, only specific bile acids can be measured. However, there are problems that the pretreatment is complicated and the separation is insufficient, and that the sensitivity is low for measuring the blood concentration. In order to solve these problems, a simple, highly specific and sensitive method using 3α-HSDH has been adopted for the measurement of total bile acid. The enzymatic method for bile acid determination is excellent as a routine routine test method and mass screening method.
3α−HSDHは、従来より数多くの報文に記載されて
いる。3α-HSDH has been described in many reports in the past.
動物起源のものとしてはラットの肝,腎臓,睾丸,前立
腺,ウサギの肝、ヒトの前立腺にその存在が証明されて
いるが、工業適な実用性に乏しい。As animal origin, its existence has been proved in rat liver, kidney, testis, prostate, rabbit liver, human prostate, but it is not suitable for industrial use.
一方、微生物起源のものとしては例えば、Talalay,P ら
が報告したシュードモナス・テストステロニー(Pseudo
monas testosteroni)由来の3α−HSDH(Nature,1
73巻,1189 頁,1954 年、Journal Biological Chemistr
y,218巻,675頁,1956年、Methods in Enzymology ,5
巻,512頁,1962 年、Biochemistry,4巻,1825頁,1965
年)、上島らが報告したシュードモナス・プチダ(Pseu
domonas putida)及びバチルス・スフエリカス(Bacill
us sphaericus)由来の3α−HSDH(Agricultural
Biological Chemistry ,42 巻,1577 頁,1978 年、43巻,
1521 頁,1979 年、特公昭60-22914)、同じくバチルス
・スフエリカス由来の3α−HSDH(特開昭54-1789
4)等が挙げられる。On the other hand, examples of microbial origin include Pseudomonas testosterone (Pseudo
monas testosteroni) -derived 3α-HSDH (Nature, 1
Volume 73, p. 1189, 1954, Journal Biological Chemistr
y, 218, 675, 1956, Methods in Enzymology, 5
Volume, 512 pages, 1962, Biochemistry, 4 pages, 1825 pages, 1965
, Pseudo reported by Uejima et al.
domonas putida) and Bacillus suhuerikas (Bacill
us sphaericus) -derived 3α-HSDH (Agricultural
Biological Chemistry, 42, 1577, 1978, 43,
1521, 1979, Japanese Examined Patent Publication No. Sho 60-22914), 3α-HSDH also derived from Bacillus sphaericus (JP-A-54-1789).
4) etc.
しかしながら、Talalay,Pらが報告した3α−HSDH
は至適pHが9.1 であり、金属イオン,p−クロロマーキ
ュリベンゾエートにより活性が著しく阻害されること等
により本酵素とは性質を異にする。又、上島らのシュー
ドモナス・プチダ由来の3α−HSDHは至適pHが11.
0、金属イオン,p−クロロマーキュリベンゾエートに
より活性阻害がみられる。更に、バチルス・スフエリカ
ス由来の3α−HSDHは至適pHが10.0〜10.5、安定化
に金属イオンを要求する。However, 3α-HSDH reported by Talalay, P et al.
Has an optimum pH of 9.1 and its properties are different from those of this enzyme because its activity is markedly inhibited by metal ions and p-chloromercuribenzoate. Also, the optimum pH of 3α-HSDH derived from Pseudomonas putida of Ueshima et al. Is 11.
0, metal ions, p-chloromercuribenzoate inhibit the activity. Furthermore, 3α-HSDH derived from Bacillus sphaericus has an optimum pH of 10.0 to 10.5 and requires metal ions for stabilization.
このように、従来報告された3α−HSDHは実用性,
至適pH,阻害剤,安定性等の面で問題点が多々存在し
た。特に、従来の酵素は至適pHが高い為、生体体液中の
胆汁酸測定には不利である。As described above, the previously reported 3α-HSDH is practical,
There were many problems in terms of optimum pH, inhibitors, stability, etc. In particular, the conventional enzyme has a high optimum pH, which is disadvantageous for the measurement of bile acids in biological fluids.
発明が解決しようとする問題点 前述したように、従来より胆汁酸測定用として実用に供
されている酵素、例えばシュードモナス・テストステロ
ニー由来の3α−HSDHは至適pHが9.0以上のとこ
ろにあり、臨床検査試薬としては不利な面が多い。即
ち、この酵素を用いる胆汁酸測定キットにおいては、通
常pH7.0 〜8.0 前後で酵素反応が行われる為、このp
H8.0 よりも掛け離れた至適pHを持つ酵素程、測定に充
分な量を使用しなければならないことを意味する。故
に、酵素使用量の増加はコストの面のみならず、多量に
使用することによる、往々にして夾雑する酵素及び添加
剤の悪影響を免れ得ないのである。なお且つ、試薬組成
中にはβ-NADが含まれており、この物質は溶液のp
Hがアルカリ側に傾く程不安定で分解し、測定には支障
をきたすことになる。これらの問題は、検査データが正
しく反映されないことでもある。DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention As described above, an enzyme conventionally used for bile acid measurement, for example, 3α-HSDH derived from Pseudomonas testosterone has an optimum pH of 9.0 or higher. Therefore, it has many disadvantages as a clinical test reagent. That is, in a bile acid measurement kit using this enzyme, the enzyme reaction is usually performed at about pH 7.0 to 8.0, so
It means that an enzyme having an optimum pH farther than H8.0 should be used in a sufficient amount for measurement. Therefore, the increase in the amount of enzyme used is not only in terms of cost but also the adverse effect of the enzyme and the additive, which are often contaminated, due to the large amount used. Moreover, the reagent composition contains β-NAD, and this substance is
The more H is inclined toward the alkali side, the more unstable and decomposes, which hinders the measurement. These problems are also that inspection data is not reflected correctly.
そこで本発明の目的は、生体体液中の胆汁酸の定量に有
利な胆汁酸測定用試薬を提供することにある。Therefore, an object of the present invention is to provide a reagent for measuring bile acid, which is advantageous for quantifying bile acid in biological fluid.
問題点を解決する為の手段 上記の実情により、至適pHが従来のものよりも低い3α
−HSDHの開発が強く望まれている現像をふまえ、本
発明者らはかかる欠点を補うべく生体体液中の胆汁酸測
定用に適した3α−HSDHの開発を目的として鋭意検
討した。その結果、研究の過程で意外にもノカルジア属
(Nocardia sp.No.Ch2- 1,FERM- P No.6217)に属する
微生物が上記目的に合致した酵素を産生することを見い
出し、本発明を完成するに至った。Means for Solving Problems Due to the above circumstances, the optimum pH is 3α lower than that of the conventional one.
Based on the development for which development of -HSDH is strongly desired, the present inventors have made earnest studies for the purpose of developing 3α-HSDH suitable for measuring bile acids in biological fluids in order to compensate for such drawbacks. As a result, in the course of research, it was unexpectedly found that a microorganism belonging to the genus Nocardia (Nocardia sp. No. Ch2-1, FERM-P No. 6217) produces an enzyme that meets the above-mentioned purpose, and the present invention was completed. Came to do.
ここで発見された新規な3α−HSDHは、至適pHが8.
0 〜9.0 であり前記の胆汁酸測定に伴うpHの問題点を解
決したのみならず、p−クロロマーキュリベンゾエート
等のSH試薬,金属イオンによって影響を受けず、安定
剤も特に必要としないという実用上すこぶる優れた性質
を有していたのである。The novel 3α-HSDH discovered here has an optimum pH of 8.
It is 0 to 9.0, which not only solves the above-mentioned pH problem associated with the measurement of bile acids, but is not affected by SH reagents such as p-chloromercuribenzoate and metal ions, and does not require a stabilizer. It had excellent properties.
本発明の酵素を製造する際に用いられる優れた菌株は、
ノカルジア・エスピー No.Ch2−1,FERM No.
6217であり、その菌学的性質は下記の如くである。An excellent strain used in producing the enzyme of the present invention is
Nocardia SP No. Ch2-1, FERM No.
6217 and its mycological properties are as follows.
(A)形態的性質 1)細胞の形及び大きさ:培養初期菌糸状に生育し分岐
を生じる。その後、不規則な分断が生じ細胞は桿菌状と
なる。大きさは0.8 〜1.0 μ×1.5 〜4.0 μ位である。
気菌糸を形成せず胞子のう胞子も形成しない。(A) Morphological properties 1) Cell shape and size: It grows in the shape of hyphae in the early stage of culture and diverges. After that, irregular division occurs and the cells become rod-shaped. The size is about 0.8 to 1.0 μ × 1.5 to 4.0 μ.
It does not form aerial hyphae, nor sporangiospores.
2)グラム染色性:陽性 3)抗酸性:陽性 4)運動性:無 (B)化学的組成分析 細胞壁中にmeso−ジアミノピメリン酸、アラビノース、
ガラクトースが含まれL,L −ジアミノピメリン酸、グリ
シンは含まない。2) Gram stainability: Positive 3) Anti-acidity: Positive 4) Motility: None (B) Chemical composition analysis meso-diaminopimelic acid, arabinose, in the cell wall
It contains galactose and does not contain L, L-diaminopimelic acid and glycine.
(C)各培地における生育状態 1)肉汁寒天平板培地:30℃で4日培養後、直径0.5 〜
1.0 mmの円形のコロニーを形成する。周辺は全縁もしく
は波状である。表面は平滑で半球状であり、中心部が凸
状に隆起する場合もある。色調は薄いクリーム色で不透
明である。培地中に色素は出さない。(C) Growth state in each medium 1) Meat broth agar plate medium: after culturing at 30 ° C. for 4 days, diameter 0.5 to
Form 1.0 mm round colonies. The surrounding area is full or wavy. The surface is smooth and hemispherical, and the central part may be convexly bulged. The color is pale cream and opaque. No dye appears in the medium.
2)シュークロース硝酸塩寒天培地:生育中程度で集落
の色は白色ないし薄クリーム色である。水溶性色素は出
さない。2) Sucrose nitrate agar medium: Medium growth and the color of the colony is white to light cream. No water-soluble dye is emitted.
3)グルコース、アスパラギン寒天培地:生育中程度で
集落の色はクリーム色である。水溶性色素は出さない。3) Glucose, asparagine agar medium: Medium growth, the color of the colony is cream. No water-soluble dye is emitted.
4)グリセリン、アスパラギン寒天培地:生育中程度で
集落の色は白色ないし薄クリーム色である。水溶性色素
は出さない。4) Glycerin and asparagine agar medium: Medium growth, and the color of the colony is white to light cream. No water-soluble dye is emitted.
5)スターチ無機塩寒天培地:生育中程度で集落の色は
白色ないし薄クリーム色である。水溶性色素は出さな
い。5) Starch inorganic salt agar medium: Medium growth, and the color of the colony is white to light cream. No water-soluble dye is emitted.
6)チロシン寒天培地:生育中程度で集落の色は白色な
いし薄クリーム色である。水溶性色素は出さない。6) Tyrosine agar medium: Medium growth and colony color is white to light cream. No water-soluble dye is emitted.
7)栄養寒天培地:生育良好で集落の色はクリーム色で
ある。水溶性色素は出さない。7) Nutrient agar medium: Growth is good and the color of the colony is cream. No water-soluble dye is emitted.
8)イースト麦芽寒天培地:生育良好で集落の色はクリ
ーム色である。水溶性色素は出さない。8) Yeast malt agar medium: Growth is good and the color of the colony is cream. No water-soluble dye is emitted.
9)オートミール寒天培地:生育中程度で集落の色は白
色ないし薄クリーム色である。水溶性色素は出さない。9) Oatmeal agar medium: Medium growth, and the color of the colony is white to light cream. No water-soluble dye is emitted.
(D)生理的性質 1)生育温度:15〜43℃で生育する。10℃,45℃で生育
しない。最適温度は30〜35℃である。(D) Physiological properties 1) Growth temperature: Grow at 15 to 43 ° C. Does not grow at 10 ℃ or 45 ℃. The optimum temperature is 30-35 ° C.
2)硝酸塩還元性:陽性 3)カタラーゼ:陽性 4)オキシダーゼ:陰性 5)ウレアーゼ:陽性 6)デンプン加水分解:陰性 7)ゼラチン液化:陰性 8)チロシン加水分解:陰性 9)カゼイン加水分解:陰性 10)キサンチン加水分解:陰性 11)DNAの分解:陰性 12)リトマスミルク:アルカリ性、ペプトン化、凝固共
にしない。2) Nitrate reducibility: positive 3) Catalase: positive 4) Oxidase: negative 5) Urease: positive 6) Starch hydrolysis: negative 7) Gelatin liquefaction: negative 8) Tyrosine hydrolysis: negative 9) Casein hydrolysis: negative 10 ) Xanthine hydrolysis: Negative 11) DNA degradation: Negative 12) Litmus milk: Alkaline, no peptone, no coagulation.
13)メラニン様色素の生成:無 14)エスクリン加水分解:陽性 15)Tween20,40,60,80加水分解:全て陽性 16)ペニシリン耐性試験:耐性 17)酸素に対する態度:好気性 18)無機窒素源の利用:アンモニウム塩、硝酸塩共に利
用する。13) Formation of melanin-like pigment: None 14) Esculin hydrolysis: Positive 15) Tween 20,40,60,80 Hydrolysis: All positive 16) Penicillin resistance test: Tolerance 17) Attitude toward oxygen: Aerobic 18) Inorganic nitrogen source Use of: Both ammonium salt and nitrate are used.
19)NaCl生育範囲:0〜6%で生育する。7%で生育し
ない。19) NaCl growth range: Grows at 0 to 6%. Does not grow at 7%.
20)各種炭素源の同化性(プリドハム、ゴドリーブ寒天
培地):D−グルコース、D−フラクトース、マンノー
ス、グリセリン、トレハロースを同化する。L−アラビ
ノース、D−キシロース、サッカロース、イノシット、
L−ラムノース、ラフイノース、D−ガラクトース、D
−マンニット、マルトース、ソルビットを同化しない。20) Assimilation of various carbon sources (Pridham, Godlieve agar): Assimilates D-glucose, D-fructose, mannose, glycerin and trehalose. L-arabinose, D-xylose, sucrose, inositol,
L-rhamnose, raffinose, D-galactose, D
-Do not assimilate mannite, maltose or sorbit.
21)各種糖から酸の生成:D−グルコース、マンノー
ス、D−フラクトース、トレハロース、グリセリンから
酸を生成する。L−アラビノース、D−キシロース、D
−ガラクトース、マルトース、サッカロース、ラクトー
ス、D−ソルビット、D−マンニット、イノシット、デ
ンプンから酸を生成しない。21) Production of acid from various sugars: Production of acid from D-glucose, mannose, D-fructose, trehalose and glycerin. L-arabinose, D-xylose, D
No acid is produced from galactose, maltose, saccharose, lactose, D-sorbit, D-mannitol, inosit, starch.
以上の菌学的性質をBergey′s Manual of Determinativ
e Bacteriology 第8版を参考に検討した結果、細胞壁
中にmeso- ジアミノピメリン酸、アラビノース、ガラク
トースを含み、L,L -ジアミノピメリン酸、グリシンが
含まれないこと、好気性で菌糸状によく生育し、後に分
断して桿菌状となること、抗酸性であること、胞子のう
胞子及び気菌糸を着生しないこと等から本菌はNocardia
に属する菌である。本菌は、本発明者らがノカルジア・
エスピー No.Ch 2-1(Nocardia sp.No.Ch 2-1)と命名
し、工業技術院微生物工業技術研究所に菌奇第6217号
(FERM -P No.6217)として既に寄託されている。The above-mentioned mycological properties are described in the Bergey's Manual of Determinativ
As a result of examination with reference to the 8th edition of e Bacteriology, the cell wall contains meso-diaminopimelic acid, arabinose, galactose, does not contain L, L-diaminopimelic acid, and glycine, and grows aerobically and well in a mycelial form. This bacterium is Nocardia due to its subsequent fragmentation into a bacillus-like form, acid resistance, and the absence of spore-spores and aerial hyphae.
Is a bacterium belonging to. This bacterium is
Named SP No.Ch 2-1 (Nocardia sp.No.Ch 2-1), and has been deposited in the Institute of Microbial Science and Technology of the Agency of Industrial Science and Technology as Bacteria No. 6217 (FERM -P No.6217). .
本酵素を培養液中に生成蓄積せしめるには、栄養培地に
炭素源としてグルコース、トレハロース等の糖類を、窒
素源としては肉エキス、ペプトン、酵母エキス等の有機
物を用いることができる。尚、3α−HSDHの生産に
はステロイド類の添加が必要であり、コレステロール,
β−シトステロール等を加えることが好ましい。又、無
機物としては、リン酸,マグネシウム,カリウム等が挙
げらるが、培地成分は上記成分に限定されることなくそ
の他の成分も任意に用いることができる。培養は上記成
分を含む培地で、20〜40℃付近,好気的条件下で行うこ
とが好ましい。In order to produce and accumulate the present enzyme in the culture medium, sugars such as glucose and trehalose can be used as the carbon source in the nutrient medium, and organic substances such as meat extract, peptone and yeast extract can be used as the nitrogen source. The production of 3α-HSDH requires the addition of steroids, cholesterol,
It is preferable to add β-sitosterol and the like. Further, examples of the inorganic substance include phosphoric acid, magnesium, potassium and the like, but the medium components are not limited to the above components, and other components can be arbitrarily used. Culturing is preferably carried out in a medium containing the above components under aerobic conditions at 20 to 40 ° C.
かくして15〜48時間程度で目的物3α−HSDHの蓄積
量は最大となる。本酵素は菌体内に蓄積する為、次にこ
れを抽出精製する。これは種々の公知の方法により達成
され、例えば得られた培養液を濾過助剤により濾過する
か、遠心分離により菌体を集めた後菌体を乳鉢,ダイノ
ミル,フレンチプレス,超音波等により破砕して菌体内
の3α−HSDHを抽出せしめる。しかるのち、この抽
出液を限外ろ過法による濃縮又は硫安塩析法,有機溶剤
沈澱法,透析法などの方法を駆使することによって粗酵
素液となす。Thus, the accumulated amount of the target substance 3α-HSDH becomes maximum in about 15 to 48 hours. Since this enzyme accumulates in the cells, it is then extracted and purified. This can be achieved by various known methods. For example, the obtained culture broth is filtered with a filter aid, or the cells are collected by centrifugation, and then the cells are crushed with a mortar, dynomill, French press, ultrasonic wave, etc. Then, 3α-HSDH in the cells is extracted. Then, the extract is made into a crude enzyme solution by concentrating by ultrafiltration or by making use of ammonium sulfate salting-out method, organic solvent precipitation method, dialysis method and the like.
以上のようにして得た粗酵素は、イオン交換クロマトグ
ラフイーによる吸着及び溶出,分子量の差に基づくゲル
濾過法,疎水結合クロマトグラフイー法,アフイニテイ
クロマトグラフイー法,電気泳動法など一般的な酵素の
精製法を適宜選択、組み合わせて精製される。The crude enzyme obtained as described above is generally used for adsorption and elution by ion exchange chromatography, gel filtration method based on difference in molecular weight, hydrophobic binding chromatography method, affinity chromatography method, electrophoresis method, etc. Purification is performed by appropriately selecting and combining different enzyme purification methods.
このようにして得られた、本発明の3α−HSDHの理
化学的性質は次のとおりである。The physicochemical properties of the 3α-HSDH of the present invention thus obtained are as follows.
作用 補酵素(NAD,NADP)の存在下、ステロイドの3
α位水酸基を脱水素し、3−ケトステロイドを生成させ
る。Action In the presence of coenzymes (NAD, NADP), 3 of steroid
The α-position hydroxyl group is dehydrogenated to produce a 3-ketosteroid.
基質特異性 デオキシコール酸、リトコール酸によく作用する。5α
−ステロイドと5β−ステロイドに対する反応性は等し
い。結果は第1表に示す。Substrate specificity Acts well on deoxycholic acid and lithocholic acid. 5α
-Reactivity to steroids and 5β-steroids is equal. The results are shown in Table 1.
至適pH 至適pHはpH8.0 〜9.0 である。 Optimum pH The optimum pH is pH 8.0 to 9.0.
結果を第1図に示す。The results are shown in Fig. 1.
安定pH 安定pH範囲40℃,15 分処理で、pH6.0 〜10.0であ
る。結果を第2図に示す。Stable pH Stable pH range: pH 6.0 to 10.0 after treatment at 40 ° C for 15 minutes. Results are shown in FIG.
至適温度及び熱安定性 至適温度が55〜60℃であり、pH8.5,20分処理では40℃
まで 100%の残存活性があり、50℃に保存しても60%の
活性を示す。結果を第3図及び第4図に示す。Optimum temperature and thermal stability Optimum temperature is 55-60 ℃, pH8.5, 40 ℃ in 20 minutes treatment
It has 100% residual activity up to 60% even when stored at 50 ° C. The results are shown in FIGS. 3 and 4.
阻害、活性及び安定化 p−クロロマーキュリベンゾエート,モノヨード酢酸等
のSH試薬により殆ど阻害されない。又、EDTA,2
価の金属イオンも活性に影響を与えない。結果を第2表
に示す。Inhibition, activity and stabilization Almost no inhibition by SH reagents such as p-chloromercuribenzoate and monoiodoacetic acid. Also, EDTA, 2
Valent metal ions also do not affect activity. The results are shown in Table 2.
Km値 コール酸 1.4×10-4M、デオキシコール酸 1.7×10
-5M、タウロコール酸 7.1×10-5M、β−NAD 7.4×
10-5Mである。 Km value Cholic acid 1.4 × 10 -4 M, Deoxycholic acid 1.7 × 10
-5 M, taurocholic acid 7.1 x 10 -5 M, β-NAD 7.4 x
It is 10 -5 M.
分子量 セファデックスG−100 (登録商標,フアルマシア社
製)を用いたゲル濾過法により測定した結果、分子量約
58、000 である。Molecular weight Sephadex G-100 (registered trademark, manufactured by Pharmacia) was measured by gel filtration.
It is 58,000.
等電点 アンホラインによるショ糖濃度勾配電気泳動により測定
した結果、等電点pI 4.4である。Isoelectric point The isoelectric point is pI 4.4 as measured by sucrose concentration gradient electrophoresis using an ampholine.
精製方法 培養液の菌体破砕液を、40%硫安塩析する。この沈澱を
リン酸緩衝液に溶解し透析した後、DEAEセファロース
(登録商標,ファルマシア社製)カラムに通液し吸着せ
しめ、食塩で溶出する。活性画分を限外濾過した後、リ
ン酸緩衝液で平衡化したアミノヘキシルセファロース
(登録商標,ファルマシア社製)カラムに通液し吸着せ
しめ、食塩で溶出する。更に、限外濾過により濃縮した
活性画分をセファデックスG−100 (登録商標,ファル
マシア社製)でゲル濾過を行い、次いで脱塩濃縮して本
酵素を得る。Purification method The cell disruption solution of the culture solution is salted out with 40% ammonium sulfate. The precipitate is dissolved in a phosphate buffer solution and dialyzed, then, passed through a DEAE Sepharose (registered trademark, manufactured by Pharmacia) column for adsorption, and eluted with sodium chloride. The active fraction is subjected to ultrafiltration, passed through an aminohexyl sepharose (registered trademark, Pharmacia) column equilibrated with a phosphate buffer, adsorbed, and eluted with sodium chloride. Further, the active fraction concentrated by ultrafiltration is subjected to gel filtration with Sephadex G-100 (registered trademark, manufactured by Pharmacia) and then desalted and concentrated to obtain the present enzyme.
活性測定法 コール酸ナトリウム(半井化学製)溶液(10mg/ml)
0.5ml、β−NAD(オリエンタル酵母製)溶液(30
mg/ml)0.1ml、0.1 Mトリス塩酸緩衝液(pH 8.5)
2.8 mlを石英セルにとり、これに酵素液0.02mlを添加し
37℃で反応させ、340nm に於ける吸光度増加を測定す
る。Activity measurement method Sodium cholate (manufactured by Hanai Chemical) solution (10mg / ml)
0.5 ml, β-NAD (Oriental Yeast) solution (30
mg / ml) 0.1 ml, 0.1 M Tris-HCl buffer (pH 8.5)
Transfer 2.8 ml to a quartz cell and add 0.02 ml of enzyme solution to it.
React at 37 ℃ and measure the increase in absorbance at 340nm.
1単位とは1分間に1マイクロモルのNADHを生成す
る酵素量を示す。One unit indicates the amount of enzyme that produces 1 micromol of NADH in 1 minute.
以上のように本発明の3α−HSDHは、シュードモナ
ス・テストステロニー,シュードモナス・プチダ及びバ
チルス・スフエリカス由来の3α−HSDHと多くの点
で異なっている。これらの比較を第3表に示す。As described above, the 3α-HSDH of the present invention differs from the 3α-HSDH derived from Pseudomonas testosterone, Pseudomonas putida, and Bacillus sphaericus in many respects. Table 3 shows these comparisons.
これから判るように、本酵素は至適pHが他の酵素と比較
して低いこと、SH試薬や金属イオンの影響を全く受け
ず非常に安定であること等から、本発明の3α−HSD
Hは従来のいずれの酵素とも性質を異にしており、新規
なものと断定できる。 As can be seen from this, since the optimum pH of this enzyme is lower than that of other enzymes, and it is very stable without being affected by SH reagents and metal ions, the 3α-HSD of the present invention.
H has different properties from any of the conventional enzymes and can be determined to be new.
又、本酵素は前記の精製方法により胆汁酸測定で問題と
なる夾雑酵素、例えば3β,7α,12α, 17 α−ステ
ロイドデヒドロゲナーゼ等を除去することが可能であ
り、酵素使用量が少量であることと相まって3α−ステ
ロイドのみを特異的に定量することができる。In addition, this enzyme is capable of removing contaminating enzymes, such as 3β, 7α, 12α, 17α-steroid dehydrogenase, which are problematic in the measurement of bile acids, by the above-mentioned purification method, and the amount of enzyme used is small. Combined with the above, only 3α-steroid can be specifically quantified.
本発明の3α−HSDHを用いた胆汁酸定量試薬は、該
酵素の補酵素であるNADのNADHへの変換量をNA
DHのもつ紫外部吸収によるUV測定法,酵素螢光測定
法,酵素比色測定法,酵素増幅測定法,生物発光反応系
等測定法の種類に応じ、公知の試薬組成に本発明の3α
−HSDHを処方することにより、優れた胆汁酸測定用
試薬が得られる。The bile acid assay reagent using 3α-HSDH of the present invention determines the conversion amount of NAD, which is a coenzyme of the enzyme, into NADH.
According to the kind of the measuring method such as the UV measuring method based on the ultraviolet absorption of DH, the enzyme fluorescence measuring method, the enzyme colorimetric measuring method, the enzyme amplification measuring method, the bioluminescence reaction system, etc.
By prescribing HSDH, an excellent reagent for measuring bile acid can be obtained.
猶、ここで選択される測定方法は胆汁酸を含む生体試料
の種類に左右される。例えば、血液,脳脊髄液,腹水に
おいては酵素螢光測定法又は生物発光反応系が、胆汁,
腸液ではいずれの方法でも採用されうる。しかし、胃
液,尿,糞便等は前処理を行ってから測定する必要が生
ずる。However, the measurement method selected here depends on the type of biological sample containing bile acid. For example, in blood, cerebrospinal fluid, and ascites, an enzyme fluorometric method or bioluminescence reaction system
For intestinal fluid, any method can be adopted. However, it is necessary to measure gastric juice, urine, feces, etc. after pretreatment.
以下に本発明で用いられる、好ましい試薬組成の使用態
様を挙げる。The usage modes of the preferred reagent composition used in the present invention are described below.
(1) 3α−HSDH 60単位/ β−NAD 0.3m mol/ Tris-HCl 0.10 mol/ 界面活性剤 適量 0.156m mol/の胆汁酸を含んだ試料0.2 mlに上記組成
物2.5 mlを添加して室温,15 分間反応後340nm における
吸光度を測定する。(1) 60 units of 3α-HSDH / β-NAD 0.3mmol / Tris-HCl 0.10mol / Surfactant Add 2.5ml of the above composition to 0.2ml of a sample containing an appropriate amount of 0.156mmol / bile acid at room temperature. After reacting for 15 minutes, measure the absorbance at 340 nm.
(2) Tris 0.13m mol/ 3α−HSDH 100 単位/ ジアホラーゼ 500 単位/ β−NAD 1.0m mol/ レサズリン 10μmol/ 牛血清アルブミン12.2g/ 試料(2.7 μmol/までの胆汁酸)及びNaOH溶液0.1
mol/を上記溶液に添加し、ローターにて回転させ5
秒と300 秒の螢光強度(蛍光波長600nm,励起波長550nm
)を測定する。(2) Tris 0.13mmol / 3 α-HSDH 100 unit / diaphorase 500 unit / β-NAD 1.0mmol / resazurin 10μmol / bovine serum albumin 12.2g / sample (bile acid up to 2.7μmol /) and NaOH solution 0.1
Add mol / to the above solution and rotate with a rotor 5
Fluorescence intensity of 600 and 300 seconds (fluorescence wavelength 600nm, excitation wavelength 550nm
) Is measured.
(3) 試料(12μ mol/までの胆汁酸)0.02mlとTCA溶液
(3g/)0.02mlを充分撹拌し、25℃に放置する。次
に、ルシフエラーゼ22.3mg/,FMNレダクターゼ2
単位/,FMN4μ mol/,牛血清アルブミン8g
/,リン酸0.11 mol/,デカナール0.2m mol/を
含有する液0.39mlと混ぜ、15〜20分間反応させる。更
に、β-NAD(0.8m mol/)0.02ml及び3α−HS
DH(150単位/)0.05mlを添加し、最初の20秒間の
発光強度増加をみる。(3) 0.02 ml of the sample (up to 12 μmol / bile acid) and 0.02 ml of TCA solution (3 g /) are thoroughly stirred and left at 25 ° C. Next, luciferase 22.3mg /, FMN reductase 2
Unit /, FMN 4μmol /, bovine serum albumin 8g
Mix with 0.39 ml of a liquid containing /, 0.11 mol / of phosphoric acid and 0.2 mmol of decanal, and react for 15 to 20 minutes. Furthermore, β-NAD (0.8mmol /) 0.02ml and 3α-HS
Add 0.05 ml DH (150 units /) and observe the increase in luminescence intensity for the first 20 seconds.
次に、本発明の実施例を示すが、本発明はこれらにより
制限されるものではない。Next, examples of the present invention will be shown, but the present invention is not limited thereto.
実施例1 Nocardia sp.No.Ch 2-1 (FERN -P No.6217)をグルコ
ース5g/,肉エキス5g/,酵母エキス0.2 g/
及び少量の消泡剤よりなる培地(pH7.2 )200 mlを
入れた500 ml容の坂口フラスコに植菌し、30℃で24時間
振盪培養した。この種培養液をコレステエロース5g/
,グルコース2g/,肉エキス5g/,リン酸水
素カリウム5g/,硫酸マグネシウム0.2 g/及び
消泡剤0.5 g/の組成より成る培地(pH7.2 )20を
入れた30容ジャーファメンターに植菌し、30℃で通気
撹拌しながら40時間培養した。培養液を遠心分離し、得
られた菌体を0.1 Mリン酸緩衝液(pH7.0 )に懸濁しガ
ラスビーズにより菌体を破砕した。これを1000r.p.m.で
10分間遠心分離し清澄な菌体抽出液を得た。次に、硫酸
アンモニウムを40%飽和になるように加え酵素を沈澱せ
しめ、この沈澱を遠心分離で集め20mMリン酸緩衝液(pH
6.0 )100 mlに溶解した。更に、セロファンチューブで
上記と同様の緩衝液にて15時間透析し、粗酵素液を得
た。Example 1 Nocardia sp. No. Ch 2-1 (FERN-P No. 6217) was added to glucose 5 g /, meat extract 5 g /, yeast extract 0.2 g /.
And 200 ml of a medium (pH 7.2) consisting of a small amount of an antifoaming agent were inoculated into a 500 ml Sakaguchi flask, and cultured at 30 ° C. for 24 hours with shaking. This seed culture solution was mixed with 5 g of cholesterose.
, Glucose 2 g /, meat extract 5 g /, potassium hydrogen phosphate 5 g /, magnesium sulfate 0.2 g /, and defoaming agent 0.5 g //, and planted in a 30 volume jar fermenter containing a medium (pH 7.2) 20. The cells were inoculated and cultured at 30 ° C. for 40 hours with aeration and stirring. The culture solution was centrifuged, and the obtained bacterial cells were suspended in 0.1 M phosphate buffer (pH 7.0) and disrupted with glass beads. This at 1000r.pm
After centrifugation for 10 minutes, a clear cell extract was obtained. Next, ammonium sulfate was added to 40% saturation to precipitate the enzyme, and the precipitate was collected by centrifugation and 20 mM phosphate buffer (pH
6.0) It was dissolved in 100 ml. Further, it was dialyzed with a cellophane tube using the same buffer solution as above for 15 hours to obtain a crude enzyme solution.
この粗酵素液を20mMリン酸緩衝液(pH6.0 )で平衡化し
たDEAEセファロース(登録商標,ファルマシア社製)10
0 mlを充填したカラムに通液し、酵素を吸着せしめた。
洗浄後、上記緩衝液中の食塩濃度を連続的に上昇せしめ
る溶出泡(食塩濃度0〜0.5 M)によりクロマトグラフ
イーを行い活性画分を得た。活性画分は限外濾過膜によ
り脱塩・濃縮した。この濃縮液を20mMリン酸緩衝液(pH
7.0 )で平衡化したアミノヘキシルセファロース(登録
商標,ファルマシア社製)50mlを充填したカラムに通
し、吸着した酵素は0.1 M食塩を含む同緩衝液で洗浄
後、食塩濃度を0.1 〜0.4 Mに連続的に上昇させる溶出
方法により精製した。更に、この活性画分を限外濾過法
により濃縮した後、0.2 M食塩を含む10mMリン酸緩衝液
(pH8.0 )で平衡化したセファデックスG−100 (登録
商標,ファルマシア社製)2.2 ×90cmでゲル濾過を行っ
た。再び限外濾過により脱塩・濃縮した後、7.5 %アク
リルアミド(pH8.9 )によるスラブ電気泳動を行ったと
ころ、本精製により得られた3α−HSDHは単一なバ
ンドを示した。This crude enzyme solution was equilibrated with 20 mM phosphate buffer (pH 6.0) to DEAE Sepharose (registered trademark, manufactured by Pharmacia) 10
The solution was passed through a column filled with 0 ml to adsorb the enzyme.
After washing, chromatography was performed with elution bubbles (sodium salt concentration 0 to 0.5 M) that continuously increase the salt concentration in the above buffer solution to obtain an active fraction. The active fraction was desalted and concentrated with an ultrafiltration membrane. This concentrated solution was added to 20 mM phosphate buffer (pH
After passing through a column packed with 50 ml of aminohexyl sepharose (registered trademark, manufactured by Pharmacia) equilibrated with 7.0), the adsorbed enzyme was washed with the same buffer containing 0.1 M sodium chloride, and the salt concentration was continuously adjusted to 0.1 to 0.4 M. Purification was carried out by an elution method in which the concentration was increased. Further, this active fraction was concentrated by an ultrafiltration method and then equilibrated with 10 mM phosphate buffer (pH 8.0) containing 0.2 M sodium chloride, Sephadex G-100 (registered trademark, manufactured by Pharmacia) 2.2 x Gel filtration was performed at 90 cm. After desalting and concentration again by ultrafiltration, slab electrophoresis with 7.5% acrylamide (pH 8.9) was performed, and 3α-HSDH obtained by this purification showed a single band.
実施例2 実施例1で得られた培養ろ液に、DEAEセルロース(セル
バ社製)を適量加え、1時間撹拌した後ろ紙で濾過し
た。DEAEセルロースに吸着した3α−HSDHは0.3 M
食塩水で溶出せしめた後、この液をオクチルアガロース
カラム(50ml容量)に通液し、吸着させた。洗浄後、1
%コール酸ナトリウムを含む1M食塩水にて溶出し、溶
出液は限外ろ過法により脱塩,濃縮した。更に、セファ
デックスG−25(登録商標、ファルマシア社製)により
脱塩した。この精製法により得られた3α−HSDH
は、電気泳動で単一なバンドを示した。Example 2 An appropriate amount of DEAE cellulose (manufactured by Selva Co.) was added to the culture filtrate obtained in Example 1, and the mixture was stirred for 1 hour and filtered through the back paper. 3α-HSDH adsorbed on DEAE cellulose is 0.3 M
After elution with a saline solution, this solution was passed through an octyl agarose column (50 ml volume) for adsorption. After washing, 1
Elution was performed with 1M saline containing sodium cholate, and the eluate was desalted and concentrated by ultrafiltration. Further, it was desalted with Sephadex G-25 (registered trademark, manufactured by Pharmacia). 3α-HSDH obtained by this purification method
Showed a single band on electrophoresis.
実施例3 実施例1で得られた3α−HSDHを用い胆汁酸の定量
を行った。Example 3 Bile acid was quantified using the 3α-HSDH obtained in Example 1.
β−NAD(オリエンタル酵母製)4μ mole ,トリト
ンX−100 (片山化学製)1.5 mg,3α−HSDH0.2
単位を含む0.1 Mトリス塩酸緩衝液(pH8.5 )3mlに、
種々の濃度のコール酸ナトリウム(半井化学製)溶液を
0.1 ml加え、37℃で10分間反応後、340nm における吸光
度を測定した。β-NAD (manufactured by Oriental Yeast) 4 μ mole, Triton X-100 (manufactured by Katayama Kagaku) 1.5 mg, 3α-HSDH0.2
3 ml of 0.1 M Tris-HCl buffer (pH 8.5) containing the unit,
Sodium cholate (manufactured by Hanai Chemical) solutions of various concentrations
After adding 0.1 ml and reacting at 37 ° C for 10 minutes, the absorbance at 340 nm was measured.
第4表に示すように、良好な結果が得られた。As shown in Table 4, good results were obtained.
実施例4 β−NAD(オリエンタル酵母製)4μmole,トリトン
X−100 (片山化学製)1.5 mg,3α−HSDH0.2 単
位,ニトロテトラゾリウムブルー(同仁化学製)0.05m
g,ジアホラーゼ(天野製薬製)3単位を含む0.1 Mト
リス塩酸緩衝液(pH8.5 )3mlに、種々の濃度のコール
酸ナトリウム(半井化学製)溶液を0.1 ml加え、37で10
分間反応後、560nm における吸光度を測定した。 Example 4 β-NAD (Oriental Yeast) 4 μmole, Triton X-100 (Katayama Chemical Co., Ltd.) 1.5 mg, 3α-HSDH 0.2 unit, Nitrotetrazolium Blue (Dojindo Co., Ltd.) 0.05 m
g, 0.1 ml of various concentrations of sodium cholate (manufactured by Hanai Chemical) to 3 ml of 0.1 M Tris-HCl buffer (pH 8.5) containing 3 units of diaphorase (manufactured by Amano Pharmaceutical Co., Ltd.)
After reacting for minutes, the absorbance at 560 nm was measured.
第5表に示すように、良好な結果が得られた。As shown in Table 5, good results were obtained.
実施例5 3α−HSDH〔液状品及び凍結乾燥粉末(活性3単位
/mg)〕の経時的安定性を、4℃の条件で行った。 Example 5 3α-HSDH [liquid product and freeze-dried powder (3 units / mg activity)] was subjected to stability over time at 4 ° C.
第6表に、液状品の各pHに於ける安定性及び凍結乾燥粉
末の安定性を相対活性(%)で示す。Table 6 shows the stability of the liquid product at each pH and the stability of the freeze-dried powder in terms of relative activity (%).
表から明らかなように、3α−HSDHは長期間にわた
り活性を保持していることが判る。As is clear from the table, it can be seen that 3α-HSDH retains its activity for a long period of time.
発明の効果 本発明で用いられる3α−HSDHは、従来の3α−H
SDHに比べ至適pHが低い為、使用する酵素の微量化
に伴うコストの大幅な減少をうることができる他、キッ
ト中に存在する補酵素(NAD,NADP)の安定な条
件下で胆汁酸を測定することができる。 EFFECTS OF THE INVENTION The 3α-HSDH used in the present invention is the conventional 3α-HSD.
Since the optimum pH is lower than that of SDH, the cost can be greatly reduced due to the miniaturization of the enzyme used, and bile acid can be obtained under the stable conditions of coenzymes (NAD, NADP) present in the kit. Can be measured.
更に、本酵素はSH試薬,金属イオンの影響を全く受け
ず且つ安定性が高い為、試薬保存性に優れることなどの
利点を併せもつので、生体体液中の胆汁酸の定量に有利
に応用することができ、正確な検査データを提供するこ
とが可能である。Furthermore, since this enzyme is not affected by SH reagents and metal ions at all and has high stability, it has advantages such as excellent reagent storability. Therefore, it is advantageously applied to the determination of bile acids in biological fluids. It is possible to provide accurate inspection data.
第1図は、本発明で用いられる3α−HSDHのpHと
活性の関係を示す図である。 第2図は、本発明で用いられる3α−HSDHのpHと
安定性の関係を示す図である。 第3図は、本発明で用いられる3α−HSDHの反応温
度と活性の関係を示す図である。 第4図は、本発明で用いられる3α−HSDHの温度と
安定性の関係を示す図である。FIG. 1 is a diagram showing the relationship between pH and activity of 3α-HSDH used in the present invention. FIG. 2 is a diagram showing the relationship between pH and stability of 3α-HSDH used in the present invention. FIG. 3 is a diagram showing the relationship between reaction temperature and activity of 3α-HSDH used in the present invention. FIG. 4 is a diagram showing a relationship between temperature and stability of 3α-HSDH used in the present invention.
Claims (2)
至適pHが8.0〜9.0にあり、3α−ヒドロキシステロイド
に対し基質特異性を有する3α−ヒドロキシステロイド
デヒドロゲナーゼを含有する系からなることを特徴とす
る胆汁酸測定用試薬。1. Obtained by culturing a Nocardia microorganism,
A reagent for measuring bile acid, which has an optimum pH of 8.0 to 9.0 and comprises a system containing 3α-hydroxysteroid dehydrogenase having substrate specificity for 3α-hydroxysteroid.
エスピーNo.Ch2−1(Nocardia sp.No.Ch2−1)
FERM−P No.6217である特許請求の範囲第1項記
載の胆汁酸測定用試薬。2. A strain belonging to the genus Nocardia is Nocardia.
SP No.Ch2-1 (Nocardia sp.No.Ch2-1)
The reagent for measuring bile acid according to claim 1, which is FERM-P No. 6217.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60290098A JPH0644878B2 (en) | 1985-12-23 | 1985-12-23 | Bile acid measurement reagent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60290098A JPH0644878B2 (en) | 1985-12-23 | 1985-12-23 | Bile acid measurement reagent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62151199A JPS62151199A (en) | 1987-07-06 |
JPH0644878B2 true JPH0644878B2 (en) | 1994-06-15 |
Family
ID=17751765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60290098A Expired - Lifetime JPH0644878B2 (en) | 1985-12-23 | 1985-12-23 | Bile acid measurement reagent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0644878B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104359906B (en) * | 2014-11-28 | 2017-06-27 | 山东博科生物产业有限公司 | A kind of stabilization, the serum tolal bile acid detection reagent of strong antijamming capability |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57194351A (en) * | 1981-05-26 | 1982-11-29 | Shimadzu Corp | Bile acid analysing method |
-
1985
- 1985-12-23 JP JP60290098A patent/JPH0644878B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPS62151199A (en) | 1987-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4882280A (en) | Uricase and a method for the preparation thereof | |
CA1286211C (en) | Method of quantitative assay for 1,5-anhydroglucitol | |
EP0012446B1 (en) | Acidic uricase, its production and its use for the determination of uric acid | |
US4181575A (en) | Composition and method for the determination of cholesterol | |
EP0477001B1 (en) | Highly sensitive assay method for myo-inositol and composition for practicing same | |
JPS6279780A (en) | Quantitative determination of 1,5-anhydroglucitol, enzyme used therefor and production thereof | |
JP3041840B2 (en) | Novel glycerol dehydrogenase, its production method and its use | |
JP2788174B2 (en) | Novel creatine amidinohydrolase and method for producing the same | |
JPH0644878B2 (en) | Bile acid measurement reagent | |
US4889801A (en) | 3α-hydroxysteroid oxidase and quantitative analysis of 3α-hydroxysteroid making use of same | |
US5100795A (en) | Bile acid sulfate sulfatase, process for its preparation and method for assaying bile acid | |
JPH0249720B2 (en) | ||
JPH1118762A (en) | 1,5-anhydroglucitol dehydrogenase and its production | |
JPH0414957B2 (en) | ||
JPH0544273B2 (en) | ||
JPS6368079A (en) | Novel 3alpha-hydroxysteroid dehydrogenase and production thereof | |
FR2517698A1 (en) | METHOD FOR DETERMINING ETHANOLAMINE | |
JP3778603B2 (en) | Sorbitol oxidase, its production method and its use | |
JPH05168474A (en) | L-fucose dehydrogenase, method for producing the same and method for quantifying L-fucose | |
JP2520073B2 (en) | 1,5-anhydroglucitol derivative | |
JPH0218064B2 (en) | ||
JPS6046953B2 (en) | Improved production method of choline oxidase | |
JPS6053599B2 (en) | Analytical composition containing choline oxidase | |
JPH07250698A (en) | Analytical reagent and analytical method using the same | |
JPH08154698A (en) | Method for determining cholesterol using cholesterol dehydrogenase |